α-2-HS-glycoprotein is a potential marker predicting hepatitis B e antigen seroconversion in patients with chronic hepatitis B during treatment with pegylated interferon alfa-2b  

作　　者：MA Hui WANG JiangHua GUO Fang WEI Lai 

机构地区：[1]Peking University People's Hospital, Peking University Hepatology Institute, Beijing 100044, China

出　　处：《Science China(Life Sciences)》2011年第1期39-47,共9页中国科学（生命科学英文版）

基　　金：supported by the National Basic Research Program of China (Grant Nos. 2005CB522902 and 2007CB512900);the National High Technology Research and Development Program of China (Grant No. 2006AA02A410);the National Natural Science Foundation of China (Grant No. 30901256);the Beijing Natural Science Foundation (Grant No. 7102153);National Science and Technology Major Project for Infectious Diseases Control During the 11th Five-Year Plan Period (Grant Nos. 2008ZX10002-012 and 2008ZX10002-013);Peking University People’s Hospital Research Development Funds (Grant No. RDC 2009-13);Key Clinical Research Program of Ministry of Health of China

摘　　要：The efficacy of interferon (IFN) is limited in about 1/3 of patients with chronic hepatitis B (CHB). We used two-dimensional electrophoresis (2-DE)-based proteomic strategies to identify potential serum markers predicting hepatitis B e antigen (HBeAg) seroconversion in these patients during IFN therapy. Two groups of patients were enrolled: training and validation. In the training group, 2-DE experiments and subsequent identification of altered levels of proteins showed that α-2-HS-glycoprotein, leucine-rich α-2-glycoprotein, and haptoglobin were significantly upregulated as compared with baseline levels in the HBeAg seroconversion group, whereas apolipoprotein C-III precursor, leucine-rich α-2-glycoprotein, and α-albumin were downregulated in the non-seroconversion group. For patients with HBeAg seroconversion in the training group, Western blot analyses showed that α-2-HS-glycoprotein levels in 75% of patients were significantly upregulated at the end of the treatment as compared with baseline levels. Subsequent experiments in the validation group showed that α-2-HS-glycoprotein levels were significantly increased at week 4 in 83.33% of patients in the HBeAg seroconversion group. Dynamic changes in the serum level of α-2-HS-glycoprotein may be a potential early marker for predicting HBeAg seroconversion during IFN treatment for CHB.The efficacy of interferon （IFN） is limited in about 1/3 of patients with chronic hepatitis B （CHB）. We used two-dimensional electrophoresis （2-DE）-based proteomic strategies to identify potential serum markers predicting hepatitis B e antigen （HBeAg） seroconversion in these patients during IFN therapy. Two groups of patients were enrolled： training and validation. In the training group, 2-DE experiments and subsequent identification of altered levels of proteins showed that α-2-HS-glycoprotein, leucine-rich α-2-glycoprotein, and haptoglobin were significantly upregulated as compared with baseline levels in the HBeAg seroconversion group, whereas apolipoprotein C-III precursor, leucine-rich α-2-glycoprotein, and α-albumin were downregulated in the non-seroconversion group. For patients with HBeAg seroconversion in the training group, Western blot analyses showed that α-2-HS-glycoprotein levels in 75% of patients were significantly upregulated at the end of the treatment as compared with baseline levels. Subsequent experiments in the validation group showed that α-2-HS-glycoprotein levels were significantly increased at week 4 in 83.33% of patients in the HBeAg seroconversion group. Dynamic changes in the serum level of α-2-HS-glycoprotein may be a potential early marker for predicting HBeAg seroconversion during IFN treatment for CHB.

关 键 词：α-2-HS-glycoprotein pegylated interferon alfa-2b chronic hepatitis B 

分 类 号：S859.797[农业科学—临床兽医学] TQ460.4[农业科学—兽医学]